The 6 Most Common Problems in FDA Software Validation and Verification in 2026

Overview:

Software validation and verification remain common sources of compliance risk for FDA-regulated companies, especially as organizations rely more heavily on automated manufacturing systems, quality systems, electronic records, cloud platforms, SaaS applications, and interconnected digital workflows. When validation is incomplete, poorly documented, or disconnected from actual intended use, the result can be delayed implementations, weak inspection evidence, costly remediation, and increased exposure during FDA review or inspection.

That pressure has become more important in the current regulatory environment. FDA’s risk-based software assurance direction, continued Part 11 expectations, increased reliance on hosted and cloud-based systems, and the 2026 QMSR inspection environment for medical device manufacturers all reinforce the need for validation programs that are practical, defensible, and properly scaled to risk. Companies cannot afford validation packages that look complete on paper but fail to show how the system was assessed, tested, controlled, and maintained.

Many validation problems begin before testing even starts. Teams may struggle to determine which systems and data are subject to 21 CFR Part 11 or Annex 11, how much testing is appropriate, which security and audit trail controls must be verified, what evidence is needed for SaaS or cloud-hosted systems, and how to staff validation projects without creating delays or unnecessary documentation burden. These uncertainties often lead to rework, inconsistent decisions, and validation files that are difficult to defend.

This webinar will examine the six most common problems in FDA software validation and verification and provide practical strategies for avoiding them. Attendees will learn how to recognize common validation pitfalls, strengthen project planning and staffing, address regulated system features such as security, audit trails, and electronic signatures, and improve validation readiness for local, SaaS, and cloud-hosted systems.

The session is designed to help FDA-regulated professionals move from uncertainty to a more structured validation approach. By understanding where validation efforts most often break down, attendees can better protect their organizations from inefficient projects, weak documentation, 483 observations, warning letter exposure, and avoidable regulatory setbacks.

Areas covered in the session:

• Which data and systems are subject to 21 CFR Part 11 and Annex 11
• Why compliance makes good business sense.
• Details of FDA regulations/system features as applied to software: security, audit trails, electronic signatures.
• Requirements for local, SaaS, and cloud hosting
• The 6 Most Common Problems in FDA Software Validation & Verification.
• Strategies on how to avoid the most common problems.
• Advice on successful validation project staffing.
• Avoid 483 and Warning Letters.

Why should you attend?

Software validation problems rarely appear as one obvious mistake. They usually build up through unclear system scope, weak requirements, insufficient testing rationale, poor documentation, missed Part 11 controls, or uncertainty around SaaS and cloud-hosted systems. This webinar will help you recognize those weak points before they turn into rework, inspection questions, 483 observations, or warning letter exposure.

The session is especially useful because it focuses on the practical side of validation and verification. Attendees will learn where FDA-regulated companies most often struggle, how to avoid common validation pitfalls, how to think through regulated system features such as security, audit trails, and electronic signatures, and how to approach validation projects with better planning, staffing, and defensible documentation.

You should attend if your team is responsible for regulated software, quality systems, manufacturing systems, electronic records, Part 11/Annex 11 compliance, or cloud-based applications used in FDA-regulated operations. The goal is to help you move from uncertainty and “wheel spinning” to a more structured validation approach that can stand up better under FDA scrutiny.

Who should attend?

This webinar is designed to benefit following professionals across a wide range of industries regulated by the FDA, including pharmaceuticals, biotechnology, medical devices, healthcare IT, and diagnostics. Whether you are directly involved in software validation and verification or play a role in ensuring regulatory compliance, this webinar will provide valuable insights and practical strategies to enhance your processes.

• Validation Engineers
• Quality Assurance Managers
• Regulatory Affairs Specialists
• Compliance Officers
• IT Managers
• Software Development Managers
• Clinical Data Managers
• Project Managers
• Quality Control Analysts
• Manufacturing Engineers
• R&D Scientists
• Systems Analysts
• Auditors
• Product Managers
• Operations Managers